2 weeks Ago By ABMN Staff
Long Focus Capital Management LLC increased its position in Cellectis S.A. ( NASDAQ:CLLS – Free Report ) by 2.
9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,617,293 shares of the biotechnology company’s stock after buying an additional 130,000 shares during the period. Long Focus Capital Management LLC owned about 0.
08% of Cellectis worth $8,634,000 at the end of the most recent quarter. A number of other institutional investors have also bought and sold shares of CLLS. Baillie Gifford & Co.
lifted its holdings in shares of Cellectis by 1.3% in the first quarter. Baillie Gifford & Co.
now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after buying an additional 10,605 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Cellectis by 2.
9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares in the last quarter.
Finally, XTX Topco Ltd purchased a new position in shares of Cellectis during the second quarter valued at about $29,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.
Cellectis Stock Up 0.9 % Shares of CLLS opened at $2.18 on Friday.
Cellectis S.A. has a 52-week low of $0.
96 and a 52-week high of $3.77. The company has a market cap of $121.
17 million, a PE ratio of -1.69 and a beta of 3.09.
The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.
39. The business has a fifty day moving average of $2.21 and a 200 day moving average of $2.
41. Analyst Upgrades and Downgrades Several equities analysts have weighed in on the company. JMP Securities restated a “market outperform” rating and set a $6.
00 price target on shares of Cellectis in a report on Friday, May 31st. Oppenheimer reduced their price target on shares of Cellectis from $11.00 to $10.
00 and set an “outperform” rating on the stock in a research report on Wednesday, June 12th. Finally, StockNews.com started coverage on shares of Cellectis in a research note on Thursday.
They set a “sell” rating on the stock. Read Our Latest Stock Report on Cellectis Cellectis Profile ( Free Report ) Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Featured Articles Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis S.A.
( NASDAQ:CLLS – Free Report ). Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter .
.
